RAAV2tYF-GRK1-RPGR ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
90網膜色素変性症2

90. 網膜色素変性症


臨床試験数 : 147 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04850118
(ClinicalTrials.gov)
August 20215/4/2021A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR MutationsA Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control Group in Male Subjects With X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR GeneX-Linked Retinitis PigmentosaBiological: rAAV2tYF-GRK1-hRPGRcoApplied Genetic Technologies CorpNULLNot yet recruiting8 Years50 YearsMale63Phase 2/Phase 3Israel;Netherlands;United States
2NCT03316560
(ClinicalTrials.gov)
April 16, 201810/10/2017Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsA Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR GeneX-Linked Retinitis PigmentosaBiological: rAAV2tYF-GRK1-RPGRApplied Genetic Technologies CorpNULLRecruiting6 Years50 YearsMale42Phase 1/Phase 2United States